Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
August 2024—Horiba announced that it has expanded its compact hematology instrument range with the launch of three models now with erythrocyte sedimentation rate onboard. The Yumizen H550E (autoloader), H500E CT (closed tube), and H500E OT (open tube) offer combined testing for CBC with differential and ESR results from whole blood in 60 seconds.
August 2024—Machaon Diagnostics has updated its genetic panel for detecting hemophagocytic lymphohistiocytosis. The HLH genetic panel 3.0 sequences 32 genes to reflect the most current understanding of HLH in the scientific literature and includes UNC13D inversion. The panel has a turnaround time of 48 hours. Draw kits are available.
August 2024—Bio-Rad Laboratories has launched its Exact Diagnostics GBS positive and negative run controls. The independent quality controls are intended to be used with group B streptococcus molecular assays for evaluating assay performance and testing operator proficiency.
August 2024—Sysmex America announced on July 9 that longtime health care executive Dan Zortman has been named the company’s new CEO. Andy Hay, who has served as CEO since 2021, will continue to serve as chairman and president of Sysmex America with a focus on the company’s emerging Hinotori surgical robotic system business.
August 2024—Qiagen has launched its QIAseq Multimodal DNA/RNA Lib Kit. The kit enables the preparation of DNA and RNA libraries for next-generation sequencing as well as downstream target enrichment based on hybrid capture from a single sample. It offers a streamlined and rapid workflow to generate whole genome and whole transcriptome sequencing libraries from a single sample by combining chemistry optimized for DNA and RNA simultaneously.
August 2024—BioPorto Diagnostics unveiled its ProNephro AKI (NGAL) test at ADLM 2024, July 28–Aug. 1, in Chicago. The FDA 510(k)-cleared test is the first acute kidney injury biomarker test cleared for pediatric use (ages 3 months through 21 years) in the United States.
August 2024—Diasorin announced it has received 510(k) clearance from the FDA for the company’s Liaison Plex Yeast Blood Culture assay, the second molecular multiplexing panel on the Liaison Plex. The assay, which is driven by Gram stain, detects 16 pathogens commonly associated with fungemia. The Liaison Plex sample-to-answer system uses room-temperature consumables, has a hands-on time of two minutes, and produces results in less than two hours.
August 2024—TechLab, a part of SSI Diagnostica Group, announced that its C. Diff Quik Chek Complete test has received certification under European in vitro diagnostic medical device regulation. The test is a rapid membrane enzyme immunoassay designed for the simultaneous detection of Clostridioides difficile glutamate dehydrogenase antigen and toxins A and B in a single reaction well and provides GDH and toxin results within about 30 minutes.
August 2024—Clarapath, a medical robotics company headquartered in Hawthorne, NY, announced it has entered into a strategic collaboration with Mayo Clinic to advance laboratory automation. Clarapath’s SectionStar is an all-in-one tissue sectioning and transfer system that is designed to increase capacity, reliability, and consistency while minimizing the need for highly skilled labor. The collaboration combines Clarapath’s tissue solution and domain experts with the clinical insights and expertise of the Mayo Clinic to enable laboratories to digitally transform the quality, safety, cost, and throughput of their histology process.
August 2024—Quest Diagnostics launched a blood biomarker test for phosphorylated tau 217, a biomarker associated with Alzheimer’s disease. It is the latest addition to Quest’s AD-Detect portfolio of tests, which also includes tests for p-tau181, amyloid beta proteins, and apolipoprotein E isoforms.
